Fig. 6

IL-22 inhibits hepatic gluconeogenesis without affecting glucose uptake in vivo. a-c Mice were fed a HFD for 8 weeks and then injected with ad-vector or ad-IL-22 for 5 days. A glucose tracer assay in vivo was performed. Glucose turnover rates and plasma glucose levels are shown (panel a). A pyruvate tolerance test (PTT) was performed (panel b). Real-time PCR analyses of gluconeogenic genes (panel c). d-e C57BL/6 mice were fed a HFD for 8 weeks and then fasted for 4 h, followed by treatment with saline or rmIL-22 (1 μg/g) for 2 h. Real-time PCR analyses of gluconeogenic genes (panel d). Two-deoxyglucose uptake experiments in vivo were performed (panel e). Values represent the mean ± SEM (n=6-10). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the corresponding ad-IL-22-treated or rmIL-22-treated groups